Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events
| Autor: | Yvonne Richter, Anja Vogt, B.R. Jaeger, Carlos A. Labarrere, Franz Heigl, Klaus G. Parhofer, Dietrich Seidel, Michael Koch, Wolfgang Ramlow, Dorothea Nagel, E. Roeseler, Gerd Utermann |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male medicine.medical_specialty Coronary Artery Disease Cohort Studies Angina Coronary artery disease Internal medicine medicine Humans Longitudinal Studies Aged Hypolipidemic Agents biology business.industry Lipoprotein(a) Middle Aged medicine.disease Combined Modality Therapy Thrombosis Treatment Outcome Apheresis Heart failure Blood Component Removal biology.protein Cardiology Female lipids (amino acids peptides and proteins) Cardiology and Cardiovascular Medicine business Cohort study Lipoprotein |
| Zdroj: | Nature Reviews Cardiology. 6:229-239 |
| ISSN: | 1759-5010 1759-5002 |
| DOI: | 10.1038/ncpcardio1456 |
| Popis: | We investigated in a longitudinal, multicenter, cohort study whether combined lipid apheresis and lipid-lowering medication can reduce extremely high levels of lipoprotein(a) (Lp[a]) and thus prevent major adverse coronary events (MACE) more efficaciously than lipid-lowering medication alone.Eligible patients had coronary artery disease and Lp(a) levelsor =2.14 micromol/l (95th percentile). All patients received lipid-lowering medications alone until maximally tolerated doses were no longer effective, followed by combined lipid apheresis and lipid-lowering medication. The rates of the primary outcome, MACE, were recorded for both periods.A total of 120 patients were included. The mean duration of lipid-lowering therapy alone was 5.6+/-5.8 years, and that of apheresis was 5.0+/-3.6 years. Median Lp(a) concentration was reduced from 4.00 micromol/l to 1.07 micromol/l with apheresis treatment (P0.0001); the corresponding mean annual MACE rate per patient was 1.056 versus 0.144 (P0.0001).Lowering of Lp(a) levels by apheresis was efficacious and safe, and we recommend this therapy for patients in whom maximally tolerated doses of medication alone have failed to control coronary artery disease-associated events. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|